MindMed

Biotechnology ResearchNew York, United States11-50 Employees

Definium Therapeutics, formerly MindMed, operates as a biotechnology research company focused on psychiatry and brain health, pursuing precision-based approaches to psychedelic medicine. It is headquartered in New York, New York, and functions as a relatively small to mid-sized organization within the biotech sector. The company frames its mission as forging a new era of psychiatry through targeted, precision application of psychedelic therapies. 

Its rebrand to Definium Therapeutics reflects a shift in emphasis while continuing work in brain health disorders through psychedelic science. In the broader biotech landscape, the firm positions itself at the intersection of neuroscience and psychiatry, aiming to advance treatment options by applying precision medicine.

Sign up for free to view info

Email Format Employee directory